Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era

The clinical outcome of patients with human epidermal growth factor receptor 2 (HER2) amplified breast carcinoma (BC) has improved with the development of anti-HER2 targeted therapies. However, patients can experience disease recurrence after curative intent and disease progression in the metastatic...

Full description

Bibliographic Details

Published in:	Breast
Main Authors:	Pablo Mandó, Sergio G. Rivero, Manglio M. Rizzo, Marina Pinkasz, Estrella M. Levy
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Subjects:	Anti-HER2 antibodies Trastuzumab ADCC Margetuximab NK cells
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621004379